
Sign up to save your podcasts
Or
PwC's Glenn Hunzinger stops by to discuss the Pharmaceutical and life sciences deals insights: 2021 midyear outlook report, showcasing the PLS sector returned to normal deal activity with strong deal volume. Plus, Omar Ford, MD+DI's Managing Editor gives his take on the controversial Illumina/Grail merger.
4.9
77 ratings
PwC's Glenn Hunzinger stops by to discuss the Pharmaceutical and life sciences deals insights: 2021 midyear outlook report, showcasing the PLS sector returned to normal deal activity with strong deal volume. Plus, Omar Ford, MD+DI's Managing Editor gives his take on the controversial Illumina/Grail merger.
30,900 Listeners
510 Listeners
58 Listeners
111,501 Listeners
56,177 Listeners
8,723 Listeners
23 Listeners
5,337 Listeners
3,834 Listeners